When should ensifentrine be added for a patient with severe COPD (post‑bronchodilator FEV1 ≤50% predicted) and chronic bronchitis who remains symptomatic and has frequent exacerbations despite maximal inhaled therapy (long‑acting β2‑agonist plus long‑acting muscarinic antagonist with or without inhaled corticosteroid)?

When to Add Ensifentrine in Severe COPD

Add ensifentrine when a patient with severe COPD (FEV₁ ≤50% predicted) and chronic bronchitis continues to have persistent symptoms and/or frequent exacerbations despite being on maximal inhaled therapy with LABA/LAMA with or without ICS.

Clinical Context and Positioning

Ensifentrine represents a novel therapeutic option as a dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties 1. Unlike roflumilast (oral PDE4 inhibitor), ensifentrine is delivered via nebulization, which may offer advantages in terms of targeted lung delivery and tolerability.

Specific Criteria for Adding Ensifentrine

Primary Indications:

• Lung function: Post-bronchodilator FEV₁ ≤50% predicted (moderate to severe COPD)
• Phenotype: Chronic bronchitis present
• Background therapy: Already on LABA/LAMA or LABA/ICS combination therapy
• Persistent problems: Either or both:
  • Ongoing symptoms (breathlessness, cough) despite optimal bronchodilator therapy
  • Frequent exacerbations (≥2 moderate exacerbations or ≥1 hospitalization in the previous year)

Evidence Base:

The ENHANCE-1 and ENHANCE-2 trials 2 demonstrated that ensifentrine added to existing maintenance therapy (69% on LAMA, 55% on LABA) produced:

• Lung function improvement: 87-94 mL increase in average FEV₁ at 12 weeks 2, 3
• Exacerbation reduction: 43-50% reduction in moderate/severe exacerbation rate 2
• Rapid onset: Improvements visible within 24 hours and sustained through 24 weeks 3

Pooled analysis specifically showed efficacy when added to LAMA monotherapy (92 mL FEV₁ improvement) or LABA/ICS combination (74 mL improvement) 4.

Treatment Algorithm

Step 1: Optimize Current Therapy

Before adding ensifentrine, ensure the patient is on appropriate baseline therapy per GOLD guidelines 5:

• Group D patients should be on LABA/LAMA combination as first-line
• If still exacerbating on LABA/LAMA, consider escalation to triple therapy (LABA/LAMA/ICS)

Step 2: Consider Ensifentrine When:

After triple therapy (LABA/LAMA/ICS), if the patient still has:

• Persistent symptoms affecting quality of life, OR
• Continued exacerbations (≥2 moderate or ≥1 severe per year)

Alternative to roflumilast: Ensifentrine can be considered instead of roflumilast in patients with FEV₁ <50% and chronic bronchitis who continue to exacerbate 5. The GOLD guidelines recommend adding roflumilast in this scenario, but ensifentrine offers similar PDE4 inhibition plus additional PDE3 inhibition with potentially better tolerability 1, 6.

Step 3: Practical Considerations

• Delivery method: Requires standard jet nebulizer with adequate airflow (approximately 7-minute nebulization time) 1
• Dosing: 3 mg twice daily via nebulizer 1
• Monitoring: Assess response at 12 weeks (lung function, symptoms, exacerbation frequency)

Comparison with Other Add-On Therapies

The GOLD guidelines 5 suggest several options for patients failing triple therapy:

1. Roflumilast: FEV₁ <50%, chronic bronchitis, ≥1 hospitalization for exacerbation in previous year

   • Ensifentrine offers similar mechanism (PDE4 inhibition) plus bronchodilation (PDE3 inhibition)
   • May have better tolerability profile than oral roflumilast 6

2. Macrolides: Former smokers with continued exacerbations

   • Consider antibiotic resistance risk
   • Ensifentrine avoids this concern

3. N-acetylcysteine: Selected patients with chronic bronchitis 7

   • Weaker evidence base compared to ensifentrine

Important Caveats

Hepatic Impairment

Ensifentrine exposure increases approximately 2-fold in moderate to severe hepatic impairment 1. Use with caution and monitor closely in these patients.

Renal Impairment

A 25% reduction in clearance occurs in moderate renal impairment, but no dose adjustment is specified 1. Not studied in severe renal impairment or end-stage renal disease.

Combination with Roflumilast

Limited data exist on combining ensifentrine with roflumilast, though one small case series suggests tolerability 8. Exercise caution with this combination given overlapping PDE4 inhibition.

Patient Selection

The nebulized delivery requires:

• Patient ability to use nebulizer correctly
• Approximately 7 minutes twice daily for administration
• Access to appropriate nebulizer equipment

Safety Profile

Ensifentrine demonstrated adverse event rates similar to placebo in clinical trials 2, 9. Unlike ICS, it does not increase pneumonia risk, making it particularly attractive in patients at high risk for this complication 5.

The key distinguishing feature of ensifentrine is its dual mechanism—combining bronchodilation (PDE3 inhibition) with anti-inflammatory effects (PDE4 inhibition)—delivered directly to the lungs, offering benefits beyond what current maintenance therapies provide in patients with severe, symptomatic COPD and chronic bronchitis.